Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27556391 | 1.00 | ITGB1 (0.58) | ITGB1ITGA4CAPN1MMP2MMP9 | |
| SCHEMBL5693820 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4CAPN1TDP1 | |
| SCHEMBL5164570 | 0.90 | CAPN1 (0.54) | ITGB1ITGA4CAPN1MMP2MMP9 | |
| SCHEMBL27505712 | 0.90 | CAPN1 (0.54) | ITGB1ITGA4CAPN1MMP2MMP9 | |
| SCHEMBL5161704 | 0.84 | CAPN1 (0.49) | ITGB1ITGA4CAPN1TDP1 | |
| SCHEMBL5165158 | 0.84 | ITGB1 (0.74) | ITGB1ITGA4CAPN1LMNATDP1 | |
| SCHEMBL5164182 | 0.84 | ITGB1 (0.74) | ITGB1ITGA4CAPN1LMNATDP1 | |
| SCHEMBL5161249 | 0.81 | ITGB1 (0.80) | ITGB1ITGA4CAPN1 | |
| SCHEMBL5165967 | 0.81 | ITGB1 (0.57) | ITGB1ITGA4CAPN1ADORA2ALMNA | |
| SCHEMBL27506094 | 0.81 | ITGB1 (0.57) | ITGB1ITGA4CAPN1ADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1144435-B1 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| CN-1195773-C | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2005-04-06 | — | — | CN | claimed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | claimed |
| US-6407066-B1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | claimed |
| CN-1344274-A | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2002-04-10 | — | — | CN | claimed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1144435-B1 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| CN-1195773-C | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2005-04-06 | — | — | CN | disclosed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | disclosed |
| US-6407066-B1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-06-18 | — | — | US | disclosed |
| CN-1344274-A | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARM INC (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-1144435-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043413-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885CAPN1 4840/4885 |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ITGB1 207/4885ITGA4 27/4885CAPN1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.